Ascendiant Capital Markets Cuts Alzamend Neuro (NASDAQ:ALZN) Price Target to $20.00

Alzamend Neuro (NASDAQ:ALZN) had its target price reduced by equities researchers at Ascendiant Capital Markets from $32.00 to $20.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Alzamend Neuro Trading Up 5.0 %

NASDAQ ALZN opened at $0.94 on Monday. The firm’s 50 day simple moving average is $1.01 and its 200 day simple moving average is $1.34. Alzamend Neuro has a 1 year low of $0.64 and a 1 year high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. Analysts anticipate that Alzamend Neuro will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro at the end of the most recent reporting period. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.